

Anti Tuberculosis Drug Liver Injury (ATLI) : A Rare Case Should Manage Promptly

Victor Nugroho Wijaya¹, I Made Suma Wirawan²

¹General Practitioner of Wangaya General Hospital, Denpasar, Bali, Indonesia

²Postgraduate Student of Doctoral Program, of Udayana University, Denpasar, Bali, Indonesia

Abstract: Male, 55 years old with tuberculosis, came to hospital with chief of complaint nausea, and vomiting after taking an oral antituberculosis for one month. Patient with unknown liver cirrhotic before oral antituberculosis started. Icteric on the eyes and laboratory results revealed increased AST, ALT, total bilirubin and decreased liver function. Patient diagnosed with Anti Tuberculosis drug Liver Injury (ATLI) and managed as ATLI protocol. We managed the patient by continuing and reintroducing an oral antituberculosis treatment with close monitoring of serial liver function.

Keywords: antituberculosis, liver injury, ATLI

1. Background

Tuberculosis (TB) remains a major global health problems. There were an estimated 10.4 million incident TB cases of worldwide in 2015 based on WHO Tuberculosis Report 2016. Indonesia included as number two in six countries accounted for 60% of the global total between India, China, Nigeria, Pakistan, and South Africa. The total TB incidence in Indonesia is 395 (255 – 564) /100,000 with mortality rate of 40 (26-57) / 100.000 in HIV-negative TB group and 10 (7.6 – 13) / 100.000 in HIV-positive TB group.¹

The TB treatment regimen consist of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E), and Streptomycin (S) as the first line anti TB drug. Despite of the effectiveness of these drugs, they are known to induce various side effects, including liver injury, skin reactions, gastrointestinal, and neurological disorders.² The incidence of anti tuberculosis drug liver injury (ATLI) during standard multi-drug TB treatment has been reported varying from 3.0% - 34.14%.³⁻⁴ ATLI incidence in Saiful Anwar Hospital Malang, Indonesia reported in 5.4% patients.⁵

Patient with liver cirrhosis have immune dysfunction with relative derangements of cell mediated immunity. There is reticuloendothelial system dysfunction, with reduced monocyte spreading, chemotaxis, bacterial phagocytosis, and bacterial killing.⁶ Baijalet *al* found that the prevalence of tuberculosis in patients with liver cirrhosis was fifteen times higher than in the general population in Mumbai, Western India.⁷ In this study, we report a case of liver function derangement caused by drug induced in cirrhotic patient admitted in Wangaya General Hospital Denpasar, Bali.

2. Case Presentation

A 55 years old, male, admitted in Wangaya General Hospital with complains of nausea, fatigue, yellowish skin and on both eyes 3 days before. Loss of appetite was also complained, but he had no vomiting. He had dark urine and pale stools within 3 days. He also had hemoptysis one day before, but only about 10 cc. Fever, muscle aches, or any

history of melena were denied. He had loss of weight in one last month about 10 kilograms.

Past history of jaundice is denied. There is no seizure and focal neurological deficit. He was diagnosed with pulmonary tuberculosis so he was on the first month of intensive phase of antituberculosis treatment (ATT) in fixed drug combination form (Isoniazid (INH) 300 mg, Rifampicin (RIF) 600 mg, Pirazinamid (PZA) 1600 mg, and Ethambutol (EMB) 1100 mg). Other medications and traditional herbs consumption is denied. He had long term smoking habit one pack per day. Alcoholic drinking habit was none, no history of injecting drug user and blood transfusion recipient.

On physical examination, he has shortened attention span, hypersomnia, lack of awareness, mild confusion, and looked very weak. Vital signs were in normal range. His body was thin and malnourished with yellowish coloured skin. Both of sclera and anterior part of tongue were icteric. He felt pain on palpation on right hypochondriac and epigastric area of abdomen. There was slight hepatomegaly, but no splenomegaly is found. Cardiac and pulmonary examination were sound. Peripheral edema and asterixis were absent.



Figure 1: Icteric appearance on patient sclera

Laboratory examination revealed derangement of liver function test with high level of alanine transferase (ALT) and aspartate transferase (AST), 107 U/L and 144 U/L, respectively. But normal alkaline phosphatase (ALP) 94 U/dL, and gamma glutamyl transferase (GGT) 50 U/L. Total bilirubin is high (18.15 mg/dL) with direct bilirubin predominant (10 mg/dL). Total protein was low (4.8 gr/dL)

with low albumin 1.5 gr/dL. Prolonged prothrombine time (PT) 22.2 seconds (INR 2.09) and aPTT 61.7 seconds. The patient also had low random blood glucose 59 mg/dL. Serological tests of HBsAg and Anti HCV Ig were negative.

Abdominal ultrasonography revealed coarseness in echotexture of liver parenchym, signs of cholecystitis with minimal ascites.



Figure 2: Patient ultrasonography showed coarseness in echotexture of liver parenchym



Figure 3: Chest X ray photo showed infiltrates and calcification on both pulmonary areas.

Chest x-ray showed infiltrates and calcification on both pulmonary areas as consistent with old pulmonary tuberculosis imaging result. Assessment of Child-Pugh score is 12, so he had Child-Turcotte-Pugh Grade C. Treatment was done by halt the ATT regimen with planning of reintroducing ATT when patient is clinically stable and serial liver function tests become normal.

3. Discussion

This case illustrates about antituberculosis induced liver injury in cirrhosis patient. To best of our knowledge there rarity of data in describing hepatotoxicity in patient with cirrhosis especially in Indonesia. Shang P *et al* found the cumulative incidence of ATLI in China was 2.55% (2.04%-3.06%, CI 95%). Incidence of ATLI related hepatitis in United Kingdom over 30 years reported as 3%.³ But there's more number in incidence of ATLI in chronic liver disease patient. Sharma *et al* found that DILI occurred in 35 % of cohort cirrhosis patients in India.⁸

Risk factor associated with this potentially fatal complication include co-infection with HIV, hepatitis B or C, pre-existing chronic liver disease, high alcohol intake, malnutrition, advanced age (>35 years old), female sex, and slow acetylators.^{4,9} In our patient, there were risk factors such as, old age (55 years old), malnutrition (thin body and loss of 10 kg body weight), and pre-existing chronic liver disease (liver cirrhosis). Patients over 35 years old have 4 fold increased possibility of developing ATLI.⁴ Clinical symptoms of ATLI in United Kingdom reported by Abbara *et al* are nausea and vomiting (54.3%), abdominal pain (18.1%), skin complaints (17.1%), and clinical jaundice (12.4%).¹⁰ Shang *et al* showed that nausea (41.51%) and vomiting (39.62%) also being the most common symptom in ATLI followed by anorexia, dizziness, abdominal symptoms, rash/pruritus, fatigue, jaundice, and dark urine. Although nausea, anorexia, and vomiting are not specific to ATLI diagnosis, they might help clinician be more cautious about ATLI. On the other hand, there was 33.02% of ATLI patients who had asymptomatic transaminase elevation. Liver injury could be fatal when it is not recognized early or therapy is not interrupted in time.² In our patient, he had nausea, fatigue, jaundice, loss of appetite, dark urine, and pale stools within three days before admission. These symptoms are consistent with clinical data above.

Liver injury occurred in our patient when he was on the first month of ATT treatment. The first line ATT regimen (HRZE) was used. Reported in a population based prospective study in China, 71.59 % of ATLI cases were identified within 2 months after starting anti-TB treatment. The median interval between the initiation of TB treatment and the detection of ATLI was 52.5 (IQR 30, 63).² Shorter median time of onset of DILI was 12 days (4-34 days). This has been observed in cirrhosis patient with ATT regimen in India.⁸ Vigilant clinical and biochemical monitoring are mandatory to improve the outcomes of cirrhosis patients with ATT therapy. Liver function test showed high ALT (107 U/L) and high AST (144 U/L), high total bilirubin (18.15 mg/dL) with direct bilirubin (10 mg/dL) predominantly. However, level of ALP and GGT were normal. These results fulfilled the diagnostic criteria of ATLI by US DILI network.^{11,12} Low serum protein (4.8 gr/dL) with low albumin (1.5 gr/dL), prolonged prothrombine time (PT; 22.2 seconds) and INR (2.09), and hypoglycemia indicated that there was liver production capacity impairment in liver cirrhosis. Our patient was assessed as Child-Turcotte-Pugh (CTP) grade C (score 12).

There remains ongoing debate as to an adequate definition of drug induced liver injury (DILI). Diagnostic criteria of DILI by US DILI network are elevation of ALT/AST more than five times ULN, or more than three times ULN with jaundice.¹¹ Debarbhavi *et al* used other but similar criteria for DILI, i.e. (i) Documented exposure to anti-tuberculous drugs, isoniazid, rifampin, pyrazinamide, ethambutol resulting in hepatotoxicity, defined as recent onset abnormalities in liver tests (rise in bilirubin of at least 2 mg/dL, or AST or ALT > 3x ULN) or ALP > 2x ULN and (ii) Exclusion of other competing cause such as acute hepatitis A, B, C and E, autoimmune hepatitis and bile duct obstruction.¹² ALP based criteria potentially being affected by TB infection related cholestasis and hence may not be

indicative of true DILI.¹⁰ Sharma *et al* reported similar findings with our patient, median and range value in patients with cirrhosis and tuberculosis as followed: ALT (61±42 U/L), AST (76±54 U/L), total bilirubin (4.8±6.1 mg/dL), INR (1.8±0.7), CTP score (8.5±1.5).⁸ The phenomenon of liver adaptation or tolerance with mild liver transaminases increases remaining below the threshold values of liver injury is commonly observed during treatment with drugs such as statin and antituberculous medications, especially isoniazid. Despite drug continuation, liver transaminases remain stable or return to normal range, and this should not exclude the drug as likely cause of acute liver injury.¹³

Diagnosis of ATLI in cirrhotic patient is difficult because it requires the ruling out of other possibilities such as viral hepatitis or other possible causes of hepatotoxicity, elevated enzymes and bilirubin at baseline and fluctuations in enzymes level caused by underlying liver diseases may confound the diagnosis.^{2,8} As these drugs are metabolized in the liver, there is a theoretical risk of increased hepatotoxicity in patients with underlying chronic liver disease (CLD). ATT constitutes an important acute precipitating event in decompensation of underlying known or unknown liver disease in India.^{8,14} Our patient had no alcoholic drinking habit, no history of injecting drug abuse or blood transfusion recipient. Serological tests of HBsAg and Anti HCV IG were negative. Due to our laboratory limitation, we did not test for autoantibody marker and other serological markers. Diagnostic problems of DILI may therefore be solved in patients with pre-existing infections by hepatotropic viruses, since assessment of the viral load could indicate hepatitis flares rather than DILI.¹⁵ The implicated ATDs should be restarted one at a time after the AST concentration has returned to less than two times the upper limit of normal. After ALT returns to less than two times the ULN, RIF may be restarted with or without EMB. RIF should be restarted first because it is much less likely to cause hepatotoxicity than INH and is a highly effective agent. ATD should be reintroduced in lower doses than were used in the initial therapy, e.g., INH 50 mg and RIF 150 mg and then stepped up (e.g., 50–100 mg for INH and 150 mg for RIF) every 3–4 days gradually to the recommended therapeutic doses. We do not recommend the reintroduction of PZA and should be permanently discontinued. If symptoms recur or ALT increases, the last drug added should be stopped. In patients with elevated baseline ALT from preexisting liver disease, drugs should be restarted when the ALT returns to near baseline levels in the manner described above.¹⁶

4. Conclusions

Anti tuberculosis therapy should be given cautiously in patient with pre-existing liver disease. Liver function derangement usually occurred in the first and second month of ATT as initial phase. Symptoms are not specific but most of patients complain nausea, anorexia, and vomiting. Comprehensive laboratory studies are needed as to exclude other possible causalities. Drugs cessation and monitoring of clinical symptoms and liver function profiles is recommended. Re-introduction and continuing ATT could be done with close supervision.

References

- [1] World Health Organization. Global Tuberculosis Report 2016. Geneva: WHO Press.
- [2] Shang P, Xia Y, Liu F, et al. Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China. *PLoS One*. 2011;6(7), p.e21836.
- [3] Bright-Thomas RJ, Gondker AR, Morris J. and Ormerod LP. Drug-related Hepatitis in Patients Treated with Standard Anti-Tuberculosis Chemotherapy over a 30-year Period. *Int J Tuberc Lung Dis*. 2016; 20(12). pp.1621-24.
- [4] Naqvi IH, Mahmood K, Talib A, Mahmood. Antituberculosis Drug-Induced Liver Injury: An Ignored Fact, Assessment of Frequency, Patterns, Severity and Risk Factors. *Open Journal of Gastroenterology*. 2015; 5(12). p.173.
- [5] Rifai A, Herlianto B, Mustika S, Pratomo B, Supriono S. Insiden dan Gambaran Klinis Hepatitis Akibat Obat Anti Tuberkulosis di Rumah Sakit Umum Daerah Dr. Saiful Anwar Malang. *Jurnal Kedokteran Brawijaya*. 2015;28(3):238-41.
- [6] Dhiman RK, Saraswat VA, Rajekar H, Reddy C, Chawla YK. A Guide to The Management of Tuberculosis in Patients with Chronic Liver Disease. *Journal of Clinical and Experimental Hepatology*. 2012;2(3):pp.260-270.
- [7] Baijal R, Praveenkumar HR, Amarapurkar DN, Nagaraj K, Jain M. Prevalence of Tuberculosis in Patients with Cirrhosis of Liver in Western India. *Tropical doctor*. 2010;40(3): pp.163-164.
- [8] Sharma P, Tyagi P, Singla V, Bansal N, Kumar A, Arora A. Clinical and Biochemical Profile of Tuberculosis in Patients with Liver Cirrhosis. *Journal of Clinical and Experimental Hepatology*. 2015;5(1):pp.8-13.
- [9] Resende LSO, Santos-Neto ETD. Risk Factors associated with Adverse Reactions to Antituberculosis Drugs. *J Bras Pneumol*. 2015;41(1):pp.77-89.
- [10] Abbara A, Chitty S, Roe JK, et al. Drug-induced Liver Injury from Antituberculous Treatment: a Retrospective Study from a Large TB Centre in The UK. *BMC Infectious Diseases*. 2017;17(1):p.231.
- [11] Wang NT, Huang YS, Lin MH, et al. Chronic Hepatitis B Infection and Risk of Antituberculosis Drug-Induced Liver Injury: Systematic Review and Meta-Analysis. *Journal of the Chinese Medical Association*. 2016;79(7):pp.368-374.
- [12] Devarbhavi H, Singh R, Patil M, et al. Outcome and Determinants of Mortality in 269 Patients with Combination Anti-Tuberculosis Drug-Induced Liver Injury. *Journal of Gastroenterology and Hepatology*. 2013;28(1): pp.161-167.
- [13] Teschke R, Danan G. Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease. *Drug Saf*. 2016;39:729-744.
- [14] Teschke R, Danan G. Drug-Induced Liver Injury: Is Chronic Liver Disease a Risk Factor and a Clinical Issue?. *Expert Opinion on Drug Metabolism & Toxicology*. 2017;13(4):pp.425-438.

- [15] Kimmoun, E. and Samuel, D., 2002. Antituberculous drugs in patients with chronic liver disease. *Journal of gastroenterology and hepatology*, 17(s3).
- [16] Dhiman, R.K., Saraswat, V.A., Rajekar, H., Reddy, C. and Chawla, Y.K., 2012. A guide to the management of tuberculosis in patients with chronic liver disease. *Journal of clinical and experimental hepatology*, 2(3), pp.260-270

